CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
D	KRAS	Mutation	Predictive	Supports	Sensitivity/Response	Pancreatic Adenocarcinoma	SCH772984,PI3Kbeta Inhibitor AZD8186	Hayes et al., 2016
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Lapatinib,Trastuzumab	Guarneri et al., 2012
B	ERBB2	Amplification	Predictive	Does Not Support	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Lapatinib,Trastuzumab	Zardavas et al., 2015
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab,Lapatinib	Blackwell et al., 2010
B	ERBB2	Amplification	Predictive	Does Not Support	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Afatinib	Harbeck et al., 2016
B	NOTCH1	P2514FS	Prognostic	Supports	Poor Outcome	Chronic Lymphocytic Leukemia		Rossi et al., 2012
B	EZH2	Mutation	Prognostic	Supports	Better Outcome	Follicular Lymphoma		Pastore et al., 2015
B	TP53	Mutation	Prognostic	Supports	Poor Outcome	Acute Myeloid Leukemia		Middeke et al., 2016
B	AREG	Expression	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Panitumumab	Seligmann et al., 2016
B	EREG	EXPRESSION	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Panitumumab	Seligmann et al., 2016
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Gastric Adenocarcinoma	Trastuzumab	Bang et al., 2010
B	CBFB::MYH11	Fusion	Prognostic	Supports	Better Outcome	Acute Myeloid Leukemia		Estey, 2012
A	KMT2A::v	Fusion	Diagnostic	Supports	Positive	Acute Myeloid Leukemia With MLL Rearrangement		Vardiman et al., 2009
B	FLT3	D835	Predictive	Supports	Resistance	Acute Myeloid Leukemia	Quizartinib,Sorafenib	Smith et al., 2012
B	FLT3	D835	Predictive	Supports	Resistance	Acute Myeloid Leukemia	Sorafenib	Man et al., 2012
C	ERBB2	Kinase Domain Mutation	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Trastuzumab	Mazières et al., 2016
C	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Lung Small Cell Carcinoma	Trastuzumab,Irinotecan	Kinehara et al., 2015
C	ERBB2	Y772_A775DUP	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	Li et al., 2015
D	ERBB2	Y772_A775DUP	Predictive	Supports	Sensitivity/Response	Lung Carcinoma	Afatinib	Perera et al., 2009
D	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Trastuzumab Emtansine	Cretella et al., 2014
C	EGFR	G465R	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Futuximab/Modotuximab Mixture	Sánchez-Martín et al., 2016
C	EGFR	G465R	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab,Panitumumab	Sánchez-Martín et al., 2016
A	SS18::SSX1	Fusion	Diagnostic	Supports	Positive	Synovial Sarcoma		Ladanyi, 2001
A	SS18::SSX2	Fusion	Diagnostic	Supports	Positive	Synovial Sarcoma		Ladanyi, 2001
B	SS18::SSX1	Fusion	Diagnostic	Supports	Positive	Synovial Sarcoma		Pfeifer et al., 2000
B	SS18::SSX1	Fusion	Diagnostic	Supports	Positive	Synovial Sarcoma		O'Sullivan et al., 2000
B	SS18::SSX1	Fusion	Prognostic	Supports	Poor Outcome	Synovial Sarcoma		Ladanyi et al., 2002
D	EGFR	S492R	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Panitumumab,Futuximab/Modotuximab Mixture	Sánchez-Martín et al., 2016
D	EGFR	S492R	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab	Sánchez-Martín et al., 2016
B	FCGR2B	I232T	Prognostic	Supports	Poor Outcome	Breast Cancer		Norton et al., 2014
B	FCGR3A	F212V	Predictive	Does Not Support	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab	Norton et al., 2014
B	FCGR2A	H167R	Predictive	Does Not Support	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab	Norton et al., 2014
B	PML	B2 DOMAIN MUTATION	Predictive	Supports	Resistance	Acute Promyelocytic Leukemia	Tretinoin	Tomita et al., 2013
C	PML::RARA	Fusion AND PML A216V	Predictive	Supports	Resistance	Acute Promyelocytic Leukemia	Tretinoin	Goto et al., 2011
B	ERBB2	Amplification	Prognostic	Supports	Poor Outcome	Endometrial Serous Adenocarcinoma		Santin et al., 2005
C	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Endometrial Serous Adenocarcinoma	Trastuzumab	Santin et al., 2008
C	ROS1	G2032R AND CD74::ROS1 Fusion	Predictive	Supports	Resistance	Lung Adenocarcinoma	Crizotinib	Awad et al., 2013
B	NPM1	EXON 11 MUTATION	Prognostic	Supports	Poor Outcome	Acute Myeloid Leukemia		Ivey et al., 2016
C	ZMYM2::FGFR1	Fusion	Predictive	Supports	Sensitivity/Response	Myeloproliferative Neoplasm	Midostaurin	Chen et al., 2004
B	FLT3	ITD	Predictive	Supports	Resistance	Acute Promyelocytic Leukemia	Anthracycline Antineoplastic Antibiotic,Tretinoin	Lucena-Araujo et al., 2014
A	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab,Neratinib	Chan et al., 2016
A	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab	Piccart-Gebhart et al., 2005
C	BRCA1	P968FS	Predisposing	Supports	Predisposition	Breast Cancer		Salgado et al., 2013
C	BRCA1	P968FS	Predisposing	Supports	Predisposition	Ovarian Cancer		Salgado et al., 2013
B	BRAF	V600E	Diagnostic	Supports	Positive	Hairy Cell Leukemia		Tiacci et al., 2011
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Capecitabine,Lapatinib	Geyer et al., 2006
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab,Capecitabine	von Minckwitz et al., 2009
D	DDX43	Overexpression	Predictive	Supports	Resistance	Uveal Melanoma	Selumetinib,Trametinib,Mirdametinib	Ambrosini et al., 2014
B	KRAS	Mutation	Predictive	Supports	Resistance	Colorectal Cancer	Chemotherapy,Bevacizumab	Petrelli et al., 2013
B	TP53	Deleterious Mutation	Prognostic	Does Not Support	Poor Outcome	Lung Non-small Cell Carcinoma		Ma et al., 2016

Page 10 of 96

Previous Next